{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:04:06Z","timestamp":1789193046372,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"TSGH (Tri-Service General Hospital) - TAFGH (Taoyuan Armed Forces General Hospital) Joint Research Program","award":["AFTYGH-10821"],"award-info":[{"award-number":["AFTYGH-10821"]}]},{"name":"TSGH (Tri-Service General Hospital) - TAFGH (Taoyuan Armed Forces General Hospital) Joint Research Program","award":["AFTYGH-10821"],"award-info":[{"award-number":["AFTYGH-10821"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recently, low-concentration atropine (0.01%) has gained increased attention in controlling myopia progression with satisfying effects and minimal side effects. However, studies concerning responders to 0.01% atropine are limited. This retrospective observational cohort study aimed to determine the responder characteristics of 0.01% atropine in Asian children. One hundred forty children (aged between 3 and 15\u00a0years) receiving 0.01% atropine were analyzed for the factors influencing annual spherical equivalent changes (SE). The mean age was 9.13 (2.6) years, the mean baseline SE was \u2212\u00a01.56 (1.52) diopters (D), and the mean annual SE change was \u2212\u00a00.52 (0.49) D. A 58.63% responder rate (146\/249) of myopic control was achieved with 0.01% atropine in our entire cohort under the criteria of less than 0.5 D of myopic progression annually. The subjects were stratified into 4 subgroups based on a cut-off point of baseline SE of \u2212\u00a01.5 D and baseline age of 9\u00a0years. The responder rate differed significantly with the highest being the youngest with the lowest myopia subgroups. Our results demonstrated that children with myopia better than \u2212\u00a01.5 D and younger than 9\u00a0years had the highest potential to achieve successful myopic control under 0.01% atropine therapy.<\/jats:p>","DOI":"10.1038\/s41598-022-10978-3","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T18:04:11Z","timestamp":1651773851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Characteristics of responders to atropine 0.01% as treatment in Asian myopic children"],"prefix":"10.1038","volume":"12","author":[{"given":"Lung-Chi","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Wei","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Hung","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"key":"10978_CR1","doi-asserted-by":"crossref","first-page":"4395278","DOI":"10.1155\/2020\/4395278","volume":"2020","author":"ZY Xiang","year":"2020","unstructured":"Xiang, Z. Y. & Zou, H. D. Recent epidemiology study data of myopia. J. Ophthalmol. 2020, 4395278 (2020).","journal-title":"J. Ophthalmol."},{"key":"10978_CR2","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","volume":"123","author":"BA Holden","year":"2016","unstructured":"Holden, B. A. et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 123, 1036\u20131042 (2016).","journal-title":"Ophthalmology"},{"key":"10978_CR3","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1001\/archophthalmol.2009.303","volume":"127","author":"S Vitale","year":"2009","unstructured":"Vitale, S., Sperduto, R. D. & Ferris, F. L. Increased prevalence of myopia in the United States between 1971\u20131972 and 1999\u20132004. Arch. Ophthalmol. 127, 1632\u20131639 (2009).","journal-title":"Arch. Ophthalmol."},{"key":"10978_CR4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.47102\/https:\/\/doi.org\/10.47102\/annals-acadmedsg.V33N1p27","volume":"33","author":"LLK Lin","year":"2004","unstructured":"Lin, L. L. K., Shih, Y. F., Hsiao, C. K. & Chen, C. J. Prevalence of Myopia in Taiwanese schoolchildren: 1983 to 2000. Ann. Acad. Med. Singapore 33, 27\u201333 (2004).","journal-title":"Ann. Acad. Med. Singapore"},{"key":"10978_CR5","doi-asserted-by":"crossref","unstructured":"Gwiazda, J. et al. Factors associated with high myopia after 7 years of follow-up in the Correction of Myopia Evaluation Trial (COMET) cohort. in Ophthalmic Epidemiology vol. 14 230\u2013237 (Taylor and Francis Ltd., 2007).","DOI":"10.1080\/01658100701486459"},{"key":"10978_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-020-00231-4","volume":"6","author":"PN Baird","year":"2020","unstructured":"Baird, P. N. et al. Myopia. Nat. Rev. Dis. Primers 6, 1\u201320 (2020).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10978_CR7","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/S0140-6736(12)60272-4","volume":"379","author":"IG Morgan","year":"2012","unstructured":"Morgan, I. G., Ohno-Matsui, K. & Saw, S. M. Myopia. The Lancet 379, 1739\u20131748 (2012).","journal-title":"The Lancet"},{"key":"10978_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.preteyeres.2017.09.004","volume":"62","author":"IG Morgan","year":"2018","unstructured":"Morgan, I. G. et al. The epidemics of myopia: Aetiology and prevention. Prog. Retin. Eye Res. 62, 134\u2013149 (2018).","journal-title":"Prog. Retin. Eye Res."},{"key":"10978_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.preteyeres.2015.12.001","volume":"52","author":"K Ohno-Matsui","year":"2016","unstructured":"Ohno-Matsui, K., Lai, T. Y. Y., Lai, C. C. & Cheung, C. M. G. Updates of pathologic myopia. Prog. Retin. Eye Res. 52, 156\u2013187 (2016).","journal-title":"Prog. Retin. Eye Res."},{"key":"10978_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/iovs.61.4.49","volume":"61","author":"AEG Haarman","year":"2020","unstructured":"Haarman, A. E. G. et al. The complications of myopia: A review and meta-analysis. Invest. Ophthalmol. Vis. Sci. 61, 1\u20133 (2020).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10978_CR11","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ophtha.2015.11.010","volume":"123","author":"J Huang","year":"2016","unstructured":"Huang, J. et al. Efficacy comparison of 16 interventions for myopia control in children: A network meta-analysis. Ophthalmology 123, 697\u2013708 (2016).","journal-title":"Ophthalmology"},{"key":"10978_CR12","doi-asserted-by":"crossref","unstructured":"Walline, J. J. et al. Interventions to slow progression of myopia in children. Cochrane Database System. Rev. 2020, (2020).","DOI":"10.1002\/14651858.CD004916.pub4"},{"key":"10978_CR13","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","volume":"113","author":"WH Chua","year":"2006","unstructured":"Chua, W. H. et al. Atropine for the treatment of childhood myopia. Ophthalmology 113, 2285\u20132291 (2006).","journal-title":"Ophthalmology"},{"key":"10978_CR14","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1001\/jamaophthalmol.2017.1091","volume":"135","author":"Q Gong","year":"2017","unstructured":"Gong, Q. et al. Efficacy and adverse effects of atropine in childhood myopia a meta-analysis. JAMA Ophthalmol. 135, 624\u2013630 (2017).","journal-title":"JAMA Ophthalmol."},{"key":"10978_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","volume":"119","author":"A Chia","year":"2012","unstructured":"Chia, A. et al. Atropine for the treatment of childhood Myopia: Safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology 119, 347\u2013354 (2012).","journal-title":"Ophthalmology"},{"key":"10978_CR16","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1097\/OPX.0000000000000037","volume":"90","author":"J Cooper","year":"2013","unstructured":"Cooper, J., Eisenberg, N., Schulman, E. & Wang, F. M. Maximum atropine dose without clinical signs or symptoms. Optom. Vis. Sci. 90, 1467\u20131472 (2013).","journal-title":"Optom. Vis. Sci."},{"key":"10978_CR17","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1007\/s00417-018-4078-6","volume":"256","author":"O Zloto","year":"2018","unstructured":"Zloto, O. et al. Current trends among pediatric ophthalmologists to decrease myopia progression\u2014an international perspective. Graefe\u2019s Arch. Clin. Exp. Ophthalmol. 256, 2457\u20132466 (2018).","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"10978_CR18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","volume":"123","author":"A Chia","year":"2016","unstructured":"Chia, A., Lu, Q. S. & Tan, D. Five-year clinical trial on atropine for the treatment of myopia 2 myopia control with atropine 0.01% eyedrops. Ophthalmology 123, 391\u2013399 (2016).","journal-title":"Ophthalmology"},{"key":"10978_CR19","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ajo.2013.09.020","volume":"157","author":"A Chia","year":"2014","unstructured":"Chia, A. et al. Atropine for the treatment of childhood myopia: Changes after stopping atropine 0.01%, 0.1% and 0.5%. Am. J. Ophthalmol. 157, 451\u2013457 (2014).","journal-title":"Am. J. Ophthalmol."},{"key":"10978_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam, J. C. et al. Low-concentration atropine for myopia progression (LAMP) study: A randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology 126, 113\u2013124 (2019).","journal-title":"Ophthalmology"},{"key":"10978_CR21","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","volume":"127","author":"JC Yam","year":"2020","unstructured":"Yam, J. C. et al. Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: Phase 2 report. Ophthalmology 127, 910\u2013919 (2020).","journal-title":"Ophthalmology"},{"key":"10978_CR22","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1089\/jop.2015.0043","volume":"31","author":"TY Clark","year":"2015","unstructured":"Clark, T. Y. & Clark, R. A. Atropine 0.01% eyedrops significantly reduce the progression of childhood myopia. J. Ocular Pharmacol. Therap. 31, 541\u2013545 (2015).","journal-title":"J. Ocular Pharmacol. Therap."},{"key":"10978_CR23","doi-asserted-by":"publisher","first-page":"e1136","DOI":"10.1111\/aos.14166","volume":"97","author":"M Sacchi","year":"2019","unstructured":"Sacchi, M. et al. Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients. Acta Ophthalmol. 97, e1136\u2013e1140 (2019).","journal-title":"Acta Ophthalmol."},{"key":"10978_CR24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40123-019-0194-6","volume":"8","author":"L Joachimsen","year":"2019","unstructured":"Joachimsen, L. et al. A pilot study on the efficacy and safety of 0.01% atropine in german schoolchildren with progressive myopia. Ophthalmol. Therapy 8, 427\u2013433 (2019).","journal-title":"Ophthalmol. Therapy"},{"key":"10978_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-021-00822-y","author":"O Hieda","year":"2021","unstructured":"Hieda, O. et al. Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study. Jpn. J. Ophthalmol. https:\/\/doi.org\/10.1007\/s10384-021-00822-y (2021).","journal-title":"Jpn. J. Ophthalmol."},{"key":"10978_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2020.00001","volume":"11","author":"X Zhang","year":"2020","unstructured":"Zhang, X., Wang, Y., Zhou, X. & Qu, X. Analysis of factors that may affect the effect of atropine 0.01% on myopia control. Front. Pharmacol. 11, 1\u20137 (2020).","journal-title":"Front. Pharmacol."},{"key":"10978_CR27","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40123-019-00217-w","volume":"8","author":"GL Larkin","year":"2019","unstructured":"Larkin, G. L. et al. Atropine 0.01% eye drops for myopia control in American children: A multiethnic sample across three US sites. Ophthalmol. Therapy 8, 589\u2013598 (2019).","journal-title":"Ophthalmol. Therapy"},{"key":"10978_CR28","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.oftale.2018.02.006","volume":"93","author":"M Diaz-Llopis","year":"2018","unstructured":"Diaz-Llopis, M. & Pinazo-Dur\u00e1n, M. D. Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness. Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition) 93, 182\u2013185 (2018).","journal-title":"Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)"},{"key":"10978_CR29","first-page":"1657","volume":"11","author":"JS Moon","year":"2018","unstructured":"Moon, J. S. & Shin, S. Y. The diluted atropine for inhibition of myopia progression in Korean children. Int. J. Ophthalmol. 11, 1657\u20131662 (2018).","journal-title":"Int. J. Ophthalmol."},{"key":"10978_CR30","first-page":"1535","volume":"104","author":"A Fu","year":"2020","unstructured":"Fu, A. et al. Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: Low-dose atropine and myopia progression. Br. J. Ophthalmol. 104, 1535\u20131541 (2020).","journal-title":"Br. J. Ophthalmol."},{"key":"10978_CR31","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","volume":"138","author":"S Wei","year":"2020","unstructured":"Wei, S. et al. Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in chinese children a randomized clinical trial. JAMA Ophthalmol. 138, 1178\u20131184 (2020).","journal-title":"JAMA Ophthalmol."},{"key":"10978_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.01.026","author":"R Saxena","year":"2021","unstructured":"Saxena, R. et al. Atropine for the treatment of childhood myopia in india: Multicentric randomized trial. Ophthalmology https:\/\/doi.org\/10.1016\/j.ophtha.2021.01.026 (2021).","journal-title":"Ophthalmology"},{"key":"10978_CR33","doi-asserted-by":"publisher","unstructured":"Hu, D.-N. Long-Term treatment of myopia with atropine. in Myopia Updates 205\u2013209 (Springer, 1998). https:\/\/doi.org\/10.1007\/978-4-431-66959-3_39.","DOI":"10.1007\/978-4-431-66959-3_39"},{"key":"10978_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-00923-1","volume":"11","author":"I P\u00e9rez-Flores","year":"2021","unstructured":"P\u00e9rez-Flores, I. et al. A multicenter Spanish study of atropine 0.01% in childhood myopia progression. Sci. Rep. 11, 1\u20139 (2021).","journal-title":"Sci. Rep."},{"key":"10978_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100923","author":"NA Brennan","year":"2020","unstructured":"Brennan, N. A., Toubouti, Y. M., Cheng, X. & Bullimore, M. A. Efficacy in myopia control. Prog. Retinal Eye Res. https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100923 (2020).","journal-title":"Prog. Retinal Eye Res."},{"key":"10978_CR36","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.ajo.2015.01.029","volume":"159","author":"KL Loh","year":"2015","unstructured":"Loh, K. L., Lu, Q., Tan, D. & Chia, A. Risk factors for progressive myopia in the atropine therapy for Myopia Study. Am. J. Ophthalmol. 159, 945\u2013949 (2015).","journal-title":"Am. J. Ophthalmol."},{"key":"10978_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.12.036","author":"FF Li","year":"2021","unstructured":"Li, F. F. et al. Age effect on treatment responses to 0.05%, 0.025%, and 0.01% atropine: Low-concentration Atropine for Myopia Progression (LAMP) Study. Ophthalmology https:\/\/doi.org\/10.1016\/j.ophtha.2020.12.036 (2021).","journal-title":"Ophthalmology"},{"key":"10978_CR38","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/jop.2011.0027","volume":"27","author":"PC Wu","year":"2011","unstructured":"Wu, P. C., Yang, Y. H. & Fang, P. C. The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren. J. Ocul. Pharmacol. Ther. 27, 461\u2013466 (2011).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10978_CR39","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1089\/jop.2009.0135","volume":"26","author":"PC Fang","year":"2010","unstructured":"Fang, P. C., Chung, M. Y., Yu, H. J. & Wu, P. C. Prevention of myopia onset with 0.025% atropine in premyopic children. J. Ocul. Pharmacol. Ther. 26, 341\u2013345 (2010).","journal-title":"J. Ocul. Pharmacol. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10978-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10978-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10978-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T03:12:31Z","timestamp":1700536351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10978-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10978"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-10978-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,5]]},"assertion":[{"value":"16 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7380"}}